Reuters logo
BRIEF-Immune Pharmaceuticals to announce launch of Remain
2017年2月17日 / 下午2点40分 / 7 个月前

BRIEF-Immune Pharmaceuticals to announce launch of Remain

Feb 17 (Reuters) - Immune Pharmaceuticals Inc

* Immune Pharmaceuticals announces the launch of Remain ™ , an international overall survival study with Ceplene® and low dose proleukin® in remission maintenance in acute myeloid leukemia

* Patient recruitment is expected to start in later 2017

* Remain will be financed exclusively through Cytovia Inc, immuno-oncology subsidiary of Immune Pharmaceuticals

* Immune plans to enroll over 400 patients worldwide with primary endpoint being overall survival at two years

* Immune Pharma -received FDA guidance regarding design of study for US approval evaluating ceplene with low dose proleukin compared to low dose proleukin alone

* Remain will be conducted in collaboration with meda, who currently holds rights to ceplene in europe and asia Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below